These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8305004)

  • 1. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials.
    Merkatz RB; Temple R; Subel S; Feiden K; Kessler DA
    N Engl J Med; 1993 Jul; 329(4):292-6. PubMed ID: 8305004
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA policy on women in drug trials.
    Caschetta MB; Chavkin W; McGovern T
    N Engl J Med; 1993 Dec; 329(24):1815-6. PubMed ID: 8232495
    [No Abstract]   [Full Text] [Related]  

  • 3. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 4. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
    [No Abstract]   [Full Text] [Related]  

  • 5. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 6. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis vaccine on hold.
    AIDS Patient Care STDS; 2008 Apr; 22(4):350. PubMed ID: 18434950
    [No Abstract]   [Full Text] [Related]  

  • 8. New FDA policy encourages inclusion of women in clinical trials.
    Clin Pharm; 1993 Oct; 12(10):712-3. PubMed ID: 8258252
    [No Abstract]   [Full Text] [Related]  

  • 9. Females in clinical studies: where are we going?
    Uhl K; Parekh A; Kweder S
    Clin Pharmacol Ther; 2007 Apr; 81(4):600-2. PubMed ID: 17314925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation of women in clinical trials of drug therapies: a context for the controversies.
    Prout MN; Fish SS
    Medscape Womens Health; 2001 Oct; 6(5):1. PubMed ID: 11698923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare's revised clinical trial policy and clinical trial-related provisions of FDAAA: what is a sponsor to do?
    Dobbins K; Scanlan K
    Food Drug Law J; 2007; 62(4):695-708. PubMed ID: 18557226
    [No Abstract]   [Full Text] [Related]  

  • 13. Women in early phase trials: an IRB's deliberations.
    Anderson JR; Schonfeld TL; Kelso TK; Prentice ED
    IRB; 2003; 25(4):7-11. PubMed ID: 14649248
    [No Abstract]   [Full Text] [Related]  

  • 14. Women in early-phase clinical drug trials: have things changed over the past 20 years?
    Fleisch J; Fleisch MC; Thürmann PA
    Clin Pharmacol Ther; 2005 Nov; 78(5):445-52. PubMed ID: 16321610
    [No Abstract]   [Full Text] [Related]  

  • 15. Women in clinical trials.
    Merkatz RB; Temple R
    Oncology (Williston Park); 1994 Jun; 8(6):52, 57. PubMed ID: 8074983
    [No Abstract]   [Full Text] [Related]  

  • 16. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
    Alper K; Schwartz KA; Kolts RL; Khan A
    Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 18. Does exclusion or inclusion better protect women?
    Shultz MM
    J Gend Specif Med; 1998; 1(2):18-22. PubMed ID: 11281007
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL
    Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.